12:00 AM
 | 
May 20, 2013
 |  BC Week In Review  |  Company News  |  Other News

Novartis endocrine/metabolic news

A German court dismissed a suit from Novartis seeking to block the assessment of the pharma's Type II diabetes drugs in the dipeptidyl peptidase-4 (DPP-4) inhibitor (gliptin) class. Preliminary assessments on the drugs - Galvus vildagliptin and Icandra vildagliptin/metformin - are expected from the Institute...

Read the full 234 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >